Reporting Methods of Blinding in Randomized Trials Assessing Nonpharmacological Treatments by Boutron, Isabelle et al.
Reporting Methods of Blinding
in Randomized Trials Assessing
Nonpharmacological Treatments
Isabelle Boutron
1,2,3*, Lydia Guittet
1,2,3, Candice Estellat
1,2,3, David Moher
4,5, Asbjørn Hro ´bjartsson
6,
Philippe Ravaud
1,2,3
1 INSERM, U738, Paris, France, 2 Universite ´ Paris 7, UFR de Me ´decine, Paris, France, 3 AP-HP, Ho ˆpital Bichat, De ´partement d’Epide ´miologie, Biostastique et Recherche
Clinique, Paris, France, 4 Children’s Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Canada, 5 Department of Epidemiology and Community
Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Canada, 6 Nordic Cochrane Centre, Rigshospitalet, Copenhagen, Denmark
Funding: DM is funded, in part, by a
University of Ottawa Research Chair.
The funders had no role in study
design, data collection and analysis,
decision to publish, or preparation
of the manuscript.
Competing Interests: The authors
have declared that no competing
interests exist.
Academic Editor: Ian Ford,
University of Glasgow, United
Kingdom
Citation: Boutron I, Guittet L, Estellat
C, Moher D, Hro ´bjartsson A, et al.
(2007) Reporting methods of
blinding in randomized trials
assessing nonpharmacological
treatments. PLoS Med 4(2): e61.
doi:10.1371/journal.pmed.0040061
Received: September 28, 2006
Accepted: December 22, 2006
Published: February 20, 2007
Copyright:  2007 Boutron et al.
This is an open-access article
distributed under the terms of the
Creative Commons Attribution
License, which permits unrestricted
use, distribution, and reproduction
in any medium, provided the
original author and source are
credited.
Abbreviations: NPT,
nonpharmacological treatment; RCT,
randomized controlled trial
* To whom correspondence should
be addressed. E-mail: isabelle.
boutron@bch.ap-hop-paris.fr
ABSTRACT
Background
Blinding is a cornerstone of treatment evaluation. Blinding is more difficult to obtain in trials
assessing nonpharmacological treatment and frequently relies on ‘‘creative’’ (nonstandard)
methods. The purpose of this study was to systematically describe the strategies used to obtain
blinding in a sample of randomized controlled trials of nonpharmacological treatment.
Methods and Findings
We systematically searched in Medline and the Cochrane Methodology Register for
randomized controlled trials (RCTs) assessing nonpharmacological treatment with blinding,
published during 2004 in high-impact-factor journals. Data were extracted using a standardized
extraction form. We identified 145 articles, with the method of blinding described in 123 of the
reports. Methods of blinding of participants and/or health care providers and/or other
caregivers concerned mainly use of sham procedures such as simulation of surgical procedures,
similar attention-control interventions, or a placebo with a different mode of administration for
rehabilitation or psychotherapy. Trials assessing devices reported various placebo interventions
such as use of sham prosthesis, identical apparatus (e.g., identical but inactivated machine or
use of activated machine with a barrier to block the treatment), or simulation of using a device.
Blinding participants to the study hypothesis was also an important method of blinding. The
methods reported for blinding outcome assessors relied mainly on centralized assessment of
paraclinical examinations, clinical examinations (i.e., use of video, audiotape, photography), or
adjudications of clinical events.
Conclusions
This study classifies blinding methods and provides a detailed description of methods that
could overcome some barriers of blinding in clinical trials assessing nonpharmacological
treatment, and provides information for readers assessing the quality of results of such trials.
The Editors’ Summary of this article follows the references.
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Bias in clinical research can be described as systematic
error that can result in false treatment effect estimates [1].
Bias may cause a investigators to misinterpret the result of
any research ﬁnding. Randomized controlled trials (RCTs) are
widely recognized as being the best design for avoiding and/or
minimizing bias. Blinding, although not possible in every
study, is an important methodological technique to help
reduce the inﬂuence bias may have on the results of an
evaluation [2–9]. Blinding refers to keeping key persons, such
as participants, health care providers, and outcome assessors,
unaware of the treatment administered or of the true
hypothesis of the trial [3,5,6]. Blinding of participants and
health care providers prevents performance bias that occurs
if additional therapeutic interventions (i.e., cointerventions)
are provided preferentially in one of the comparison groups
[10]. Blinding of outcome assessors minimizes the risk of
detection bias (i.e., observer, ascertainment, assessment bias).
This type of bias occurs if participant assignment inﬂuences
the process of outcome assessment [10]. For example, non-
blinded neurologists assessing the outcome from a trial [9]
demonstrated an apparent treatment beneﬁt, whereas
blinded neurologists did not. Finally, blinding of data analysts
can also prevent bias, as knowledge of the intervention
received may inﬂuence the choice of analytical strategies and
methods [10]. Empirical evidence has demonstrated that lack
of reporting of double blinding is responsible for biased
treatment estimates [1,2,11–13].
However, blinding might be difﬁcult or impossible to
establish and/or to maintain [14–16], and a blinding proce-
dure might fail [17,18]. Therefore, researchers and readers
must be aware of existing methods of blinding to be able to
appraise the feasibility of blinding in a trial.
Nonpharmacological treatment (NPT) such as surgery,
technical interventions, rehabilitation, behavioral interven-
tions, psychotherapy, and use of devices represent a wide
range of treatment options. Assessing NPT raises speciﬁc
methodological issues [19–26]. Blinding is less frequently
reported in RCTs assessing NPT [19], possibly due to the
difﬁculty in achieving and maintaining it [18] and a lack of
knowledge about existing methods in the ﬁeld. Here, we
present an inventory and classiﬁcation scheme of reported
methods of blinding procedures used in NPT trials.
Methods
Domain of Interest and Defining NPT
We assessed the reporting of blinding and the method of
blinding participants, health care providers (i.e., those
administering the treatment), and outcome assessors (i.e.,
those assessing the main outcome). Our assessment included
the blinding status of other caregivers such as physicians
administering cointerventions because they may have an
important inﬂuence on treatment effect in trials assessing
NPT. For example, in a trial assessing a surgical procedure,
even if the surgeon could not be blinded, it is possible that
the health care professionals following participants after the
procedure could be blinded, and contact between other
caregivers and the surgeon could be avoided. We did not
focus on other key trial participants such as data analysts,
because there is no barrier for blinding data analysts in trials
assessing NPT. Furthermore, we did not provide data on the
methods of blinding data collectors, because this information
is usually poorly reported, and consistently identifying data
collectors in articles is difﬁcult [27].
NPT is deﬁned as any intervention(s) provided to partic-
ipants that involves treatments other than the use of
pharmaceuticals. These treatments include, for example,
surgery, technical operations (e.g., angioplasty, joint lavage),
implanted devices (pacemaker, stent, ventriculoperitoneal
shunt, ear tube, or prosthetic device), nonimplantable
devices, rehabilitation, behavioral therapy, and psychother-
apy but not the organization of the health care system or
interventions provided to health care providers.
Identification of Reports
We identiﬁed reports of all RCTs published in 2004 in the
ten highest impact factor general and internal medicine
journals and the three highest impact factors for each subject
category of the Journal Citation Reports (Journal citation
reports, http://isiwebofknowledge.com) such as cardiac and
cardiovascular system, respiratory system, or rheumatology
and indexed in Medline by searching PubMed (http://www.
ncbi.nlm.nih.gov/entrez/query.fcgi) using the terms ‘‘double-
blind method’’ OR ‘‘single-blind method,’’ limited to RCTs
(Text S1). We chose these journals because a high impact
factor is a good predictor of high methodological quality of
journal articles [28]. We also searched for reports on blinding
indexed in the Cochrane Methodology Register (Cochrane
Library, Issue 1, 2005, http://www3.cochrane.org/access_data/
cmr/accessDB_cmr.asp) using the term ‘‘blind,’’ with no
limitation linked to the year of publication but a language
limitation (English or French).
Eligibility Criteria and Screening
We collected records in an EndNote data ﬁle, and one of us
(IB) assessed each one by screening the titles and abstracts to
identify the relevant studies. Full articles were retrieved for
further assessment if the information given suggested that the
study was a randomized controlled trial assessing NPT. If
there was any doubt regarding these criteria from the
information given in the title and abstract, the full article
was retrieved for clariﬁcation.
After obtaining the full text, we further selected reports
only if they reported that participants, health care providers,
other caregivers, or outcome assessors were blinded. We
excluded nonrandomized trials, extended follow-up trials
(i.e., extended follow-up of patients included in an RCT
beyond the last outcome assessment), diagnostic accuracy
studies, pathophysiological studies, an RCT ancillary study
(such as a subgroup analysis, cost-effectiveness evaluations,
systematic reviews and/or meta-analyses), and any trials
assessing pharmacological treatment. However, trials com-
paring nonpharmacological and pharmacological treatments
were selected.
Additional relevant trials were found by searching refer-
ence lists of relevant selected reports or those that were
known by members of our team or experts in this ﬁeld, with
no limitation linked to the year of publication.
Data Collection
From a review of the relevant literature, we generated a
standardized data collection form that was iterated among
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Methods of Blindingthe research team. Before data extraction, as a calibration
exercise, two members of the team (IB, LG) independently
evaluated a separate set of ten reports. A meeting followed in
which the ratings were reviewed and any disagreements were
resolved by consensus. One reviewer (IB) independently
completed all the data extractions. A second member of the
team reviewed a random sample of 30 articles as a quality
assurance exercise. The reproducibility was good, with the
rate of agreement higher than 85% for the main items.
The form included 46 items (available upon request) that
described the experimental treatment (nonimplantable de-
vices, surgery and technical operation, implantable devices,
rehabilitation, education, diet, psychotherapy) and the con-
trol treatment (placebo, active control treatment, usual care).
We classiﬁed the NPT using three categories based on our
experience, according to the difﬁculties of blinding: (1)
surgery or technical procedures, (2) participative interven-
tions such as rehabilitation, education, or psychotherapy
involving a collaboration between participants and care
providers, and (3) devices.
We identiﬁed and classiﬁed the primary outcome as a
participant-reported outcome according to speciﬁc criteria
[18]: the participant as the outcome assessor (e.g., pain,
disability, quality of life), physician-driven data that assume
contact between participants and outcome assessors (e.g.,
range of motion), complementary investigations that do not
assume contact between participants and outcome assessors
(e.g., international normalized ratios within the target range,
angiographic restenosis) or a clinical event determined by the
interaction between participants and care providers (e.g.,
death, myocardial infarction, stroke, dialysis, blood trans-
fusion).
We extracted the reported blinding status for participants,
health care providers, other caregivers, and outcome asses-
sors and checked whether the blinding method(s) were
described and, if so, how. Each report was reviewed for any
description of a sham procedure; an attempt to blind
participants, health care providers, or outcome assessors to
the hypothesis; or an attempt to blind other caregivers who
did not perform the treatment but administered cointerven-
tions. Finally, we recorded the description of speciﬁc
methods of blinded outcome assessments, such as partici-
pants being informed not to reveal to the outcome assessors
what intervention they received and whether the success of
blinding was tested.
Classification of the Methods of Blinding
We classiﬁed how blinding was achieved for participants,
health care providers, and the main outcome assessor mainly
on the basis of what seemed reasonable after having read
through the various methods of blinding.
Statistical Analysis
Descriptive statistics for categorical variables were de-
scribed with frequencies and percentages. All data analyses
involved SAS for Windows, Release 9.1 (http://www.sas.com).
Results
Articles Selected
Our electronic search retrieved 1,040 records. We identi-
ﬁed 83 reports on the basis of the title and abstract and 61
articles by personal identiﬁcation and use of references.
Finally, we analyzed 123 reports describing a blinding method
(Figure 1).
Characteristics of the Included Articles
Table 1 describes the characteristics of the included
articles. These reports assessed devices (n ¼ 59; 48%),
participative interventions (i.e., interventions involving a
collaboration between participants and care providers) such
as rehabilitation, education, psychotherapy (n ¼ 33; 27%),
surgery or technical interventions (n ¼ 20; 16%), or other
NPT such as preoperative autologous blood donation,
hyperbaric oxygen therapy, or blood patch (n ¼ 11; 9%). A
total of 59% of reports (n¼73) clearly described blinding for
participants, 31% (n ¼ 39) health care providers or other
caregivers, and 86% (n¼105) outcome assessors. Twenty-one
reports (17%) assessed the success of blinding.
Method of Blinding
Use of sham procedures. Almost half the reports (58%; n¼
71) described the use of a sham procedure, 80% of the 59
reports assessing a device, 45% of the 20 reports assessing a
surgical procedure, 36% of the 33 reports assessing partic-
ipative interventions and 27% of the 11 reports on other
NPT. Figure 2 describes these sham procedures according to
the treatment assessed. Table S1 provides examples of
reporting of sham procedures.
For surgical interventions, the sham procedures consisted
mainly of simulating the intervention, including ‘‘standard-
izing’’ the postoperative care. For example, in one study, a
sham procedure was performed in the control arm to assess
Figure 1. Flow of Records, Citations, and Articles through the Cross-
Sectional Study
doi:10.1371/journal.pmed.0040061.g001
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Methods of Blindingthe efﬁcacy of transplantation of embryonic dopamine
neurons in Parkinson’s disease. Participants receiving the
sham procedure underwent a procedure of the same nature
(i.e., ‘‘four twist-drill holes made through the frontal bone
after local anesthesia to place tissue implants with the use of
a stainless-steel guide cannula, except that the dura mater
was not penetrated after the twist-drill holes were made’’)
[29].
For participative interventions, the sham procedures were
either an attention-control intervention of the same nature
or a placebo with a different mode of administration. For
example, one study involved the use of hands-on procedures
to simulate manipulation [30], with the participant lying
prone and soft-tissue massage and gentle palpation applied to
the spine, paraspinal muscles, and shoulders. In a trial
assessing physiotherapy for knee osteoarthritis with an active
treatment consisting of knee taping, massage, spine mobi-
lization, and exercise, the placebo treatment was sham
ultrasonography and light application of a nontherapeutic
gel. Participants in the active and control arms did not attend
treatment and assessment concurrently [31].
Reports of trials assessing devices also described various
placebo interventions, such as use of sham prosthesis,
identical apparatus, or simulation of a device. An identical
apparatus consisted of an identical inactivated machine such
as a detuned ultrasound machine or an activated machine
with a barrier to block the treatment. For example, in a study
assessing a high-strength magnetic knee sleeve for the
treatment of knee osteoarthritis [32], the placebo knee sleeve
was designed to provide a strong magnetic ﬁeld on the
surface facing away from the knee joint, thereby making it
appear to offer magnetic therapy but to impart no signiﬁcant
magnetic ﬁeld to the knee joint. Quality control procedures
demonstrated that although the machine was activated, the
treated area was not exposed to the treatment.
Some placebo devices were developed to mimic the actual
use of a device. In a study assessing a prosorba column that
involved routing the tubing that drew off the blood behind a
curtain where the prosorba column was situated, in partic-
ipants assigned to the sham apheresis, plasma was passed
instead to a transfer bag, which had the same volume as the
prosorba column. Plasma processing time was matched to
that of the active treatment. Some reports described the use
of opaque goggles (e.g., assessment of laser therapy), eyes
covered with patches, speciﬁc positioning of participants to
prevent them from seeing the treatment, or use of curtains or
boxes to blind a device (see Figure 2). Because the sham
procedure was not strictly identical to the experimental
treatment, some authors attempted to assess the credibility of
the treatment (n ¼ 4).
Table 1. Characteristics of the Included Articles to Assess Blinding in Reports of Trials Investigating Nonpharmacologic Treatment
Category Subcategory Number (n ¼ 123) Percentage
Clinical domain Musculoskeletal system 45 37
Anesthesiology/pain/critical care 14 11
Cardiac and cardiovascular system 14 11
Psychiatry/psychology 9 7
Respiratory system 6 5
Neurology 86
Gastroenterology and hepatology 6 5
Dermatology 43
Other 17 15
Experimental treatment Devices 59 48
Surgery 20 16
Participative intervention 33 27
Other 11 9
Control treatment Placebo only 58 47
Active control treatment only 32 26
Usual care only 17 14
Placebo and active control treatment 12 9
Placebo and usual care 1 1
Active control treatment and usual care 2 2
Placebo and active control treatment and usual care 1 1
Blinding status Participants only 43
Health care providers or other care givers only 2 2
Outcome assessors only 34 28
Participants and health care providers or other care givers 0 0
Participants and outcome assessors 34 28
Health care providers or other care givers and outcome assessors 2 2
Participants and health care providers or other care givers and outcome assessors 35 28
Unclear 12 9
Main outcomes Participant-reported outcome only 46 37
Physician-driven data only 24 19
Paraclinical examination only 7 7
Clinical event only 17 14
Multiple outcomes 25 20
Unclear 43
doi:10.1371/journal.pmed.0040061.t001
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Methods of BlindingBlinding to study hypothesis. Blinding participants to the
study hypothesis was reported in 12 studies (10%). This
method was proposed either with the use of a sham procedure
or when participants and/or health care providers could not
be blinded to the treatment they received. These methods
consisted of partial information given to participants (n¼11)
and use of a modiﬁed Zelen design (n¼1). Partial information
given to participants consisted of not informing them about
the existence of a placebo, the nature of the placebo, or the
purpose of the study. In a trial assessing rehabilitation for
stroke participants, participants were aware that two proce-
dures were being compared but not that one treatment was a
control, because neither the consent forms nor the verbal
explanations referred to the attention control intervention as
a control treatment. Thus, participants could reasonably
expect an improvement regardless of treatment received. One
report described a modiﬁed Zelen design [33] to blind
participants to the study hypothesis in a trial comparing
usual care to a complex, physical therapy-based intervention
for patellofemoral joint osteoarthritis of the knee [33]. First,
researchers invited participants to participate in a cohort.
Then they informed participants randomized to the inter-
vention arm that they would receive the experimental treat-
ment, and they signed a second consent form.
Figure 2. Sham Procedure Performed According to the Category of Treatment Assessed
doi:10.1371/journal.pmed.0040061.g002
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Methods of BlindingIn one trial assessing cognitive behavioral therapy, two
junior clinical psychologists, unaware of behavioral insomnia
therapy, were blinded to the study hypothesis. They were not
told that one of the treatments they administered was a
placebo. Once all participants completed treatment, the
investigative team debriefed the therapists about the study
hypotheses and placebo treatment [34]. Table S2 provides
examples of reporting methods of blinding participants of
study hypotheses.
To avoid nonblinding because of speciﬁc treatment side
effects, such as speciﬁc sensation with a transcutaneous
electrical nerve stimulator),e x c l u d e dp a r t i c i p a n t sw i t h
previous experience of the intervention, and avoided treat-
ment crossovers, but also provided only partial information
to participants of the potential manifestations linked to
treatments (n ¼ 6). When assessing parental auricular
acupuncture [35], the research assistant informed partici-
pants that they may experience a pinching sensation with
insertion of the needles and ‘‘incorrectly’’ informed them
that this sensation was not related to group assignment.
Blinded centralized assessment of the primary outcome. A
total of 43 reports (35%) described speciﬁc methods to blind
outcome assessors. These methods relied mainly on a
centralized assessment of the main outcome. They relied on
physician-driven data of a centralized assessment of clinical
examination provided through video, audiotape, or photog-
raphy (n ¼ 9). To assess the analgesic effect of breast-feeding
in term neonates compared to mothers’ arms, paciﬁers,
placebo (i.e., sterile water), or glucose [36], the researchers
videotaped the infants and the monitor screen during the
procedure, and two specially trained observers independently
assessed the recordings using a speciﬁc scale. The observers
were blind as to the purpose and study hypothesis but had
been told that they were assessing agreement of their scores
in four different situations. Finally, for physician-driven data,
other methods of blinding included masking a scar by a hat or
sham dressing (n ¼ 4) or asking participants not to tell the
outcome assessor what treatment they received (n¼13). Table
S3 describes examples of reporting methods of blinding
outcome assessors.
For paraclinical examination, methods of blinding relied
on a centralized assessment of complementary investigation
(n ¼ 13) such as centralized assessment of angiogram. For
clinical events blinding relied on assessment of events by a
blinded adjudication committee (n ¼ 7) or a blinded assess-
ment of the extract of the case report form by an investigator
(n ¼ 3).
Classification of the Methods of Blinding
Our results helped us developed a classiﬁcation scheme to
distinguish between: (1) the blinding of key trial person—
participants, health care providers, or other caregivers—that
rely on the category of treatment (surgical/technical proce-
dure, participative interventions, devices) and comparator
assessed (Figure 3), and (2) the blinding of outcome assessors
depending on the primary outcome considered (Figure 4).
Although other classiﬁcation systems are possible, we elected
to focus on the category of treatment, the comparator, and
the primary outcomes, believing them to be more practical
for those planning RCTs that involve blinding. However,
other ways of classifying could be analysed and discussed in
further studies.
Discussion
This study provides a detailed description and classiﬁca-
tion, with examples of reporting, of different methods of
blinding participants, health care providers or other care-
givers, and outcome assessors in a large series of RCTs
assessing NPT. Our results highlight innovative methods of
blinding and allow for a description of possible placebos for
NPT in trials.
Although evidence has demonstrated that lack of blinding
could bias treatment effect estimates, reports of RCTs
describe blinding poorly [4,14,16,17] especially RCTs assess-
ing NPTs [18,19]. Lack of blinding in trials assessing NPTs is
probably associated, in part, with a lack of awareness of
existing methods of blinding. To improve this situation, we
developed an inventory of blinding methods and classiﬁed
them according to what seemed reasonable after having read
through the various methods. We hope that disseminating
this classiﬁcation scheme along with the detailed examples of
reporting (Tables S1–S3) will help clinical trialists better
integrate blinding into the design and conduct of their trials.
As well, those critically appraising the health care literature
need adequate knowledge of all possible methods of blinding
to be able to determine the feasibility of blinding in a
published report of an RCT [37].
Use of a placebo is a standard method to blind
participants and health care providers in RCTs. Although
fabrication of placebo is relatively easy for pharmacological
treatment, it is more difﬁcult for surgery, rehabilitation, or
psychotherapy. Our review identiﬁed several ingenious
placebo methods, such as sham surgery, sham manipulation,
or sham acupuncture. However, these methods raise some
issues. First, the use of sham procedures in surgery is
debatable, because it is not without risk, such as with general
anesthesia and intraoperative procedures. Moreover, the
optimal placebo should appear exactly like the ‘‘real’’
treatment but lack the ‘‘supposed’’ speciﬁc component.
Debate surrounds the use of attention-control interventions
in trials assessing participative intervention, because these
treatments have a speciﬁc therapeutic effect linked, for
instance, to the relationship between participants and health
care providers. Consequently, the use of attention-control
interventions could underestimate the treatment effect [38].
Finally, use of placebo for NPT could be a barrier for the
participation of patients and health care providers in such a
trial. A selection bias might have been introduced in the
RCT assessing arthroscopy surgery for osteoarthritis of the
knee because 44% of the eligible patients declined to
participate in the study. This high rate of refusal to
participate probably resulted from the fact that all patients
knew they had a one-in-three chance of undergoing a
placebo procedure [39].
Some researchers reported using a placebo control
intervention that was not identical to the active treatment,
for example, in comparing an experimental rehabilitation
program to sham ultrasonography. These methods could be a
solution when assessing NPT. Spigt et al. [40], in assessing
lifestyle advice, proposed using a syrup placebo, and assessed
and validated the methodological and ethical consideration
of these designs. In such trials, participants should be
informed in part and blinded to the study hypothesis.
Blinding participants to study hypotheses could also be
PLoS Medicine | www.plosmedicine.org February 2007 | Volume 4 | Issue 2 | e61 0375
Methods of BlindingFigure 3. Methods of Blinding Participants, Health Care Providers, or Other Caregivers That Rely on the Category of Treatment and Comparator Assessed
doi:10.1371/journal.pmed.0040061.g003
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Methods of Blindingproposed when the comparator is an active control treat-
ment of the same nature or different nature by use of a
modiﬁed Zelen design [33,41]. Such design is a two-stage
procedure, in which patients are asked to provide consent
for an observational study in the ﬁrst stage. Then patients
are randomized to the experimental treatment and the
control arm, and in the second stage are asked to provide a
second consent for treatment. In these situations, ethical
considerations require that participants be told that for
scientiﬁc reasons, they were not informed about the speciﬁc
goal of the study and that full information will be provided
at the study’s conclusion [40,42]. Further, such trials should
be conducted carefully to avoid disclosure of the trial
hypothesis and, especially, to avoid contact between partic-
ipants in each arm. Using such a design, trialists should be
aware that depending on the appearance of the experimen-
tal treatment and placebo, differences in expectations could
inﬂuence the outcome, particularly for outcomes sensitive to
psychological factors. In these situations, the psychological
strength of the treatment could be assessed by measuring
the credibility of the treatment (i.e., use of validated
credibility scales [43,44]), participants’ expectations (i.e.,
asking participants to rate their expected effect of both
intervention on a Likert scale), or by registering partic-
ipants’ preference at the beginning of the trial before
randomization [40,45–51].
Our classiﬁcation scheme highlights the fact that blinding
outcome assessors depends mainly on the primary outcome.
We focused on the outcome because of some evidence that
the risk of bias varies according to the outcome. Wood et al.
[52] showed that lack of blinding yielded exaggerated
treatment effect estimates for subjective outcomes but had
no effect on objective outcomes. In most situations blinding
outcome assessors should therefore be possible with a
centralized assessment of complementary investigation,
physician-mediated data, and clinical events (Figure 4).
These methods are likely to be more successful than those
consisting of instructing participants not to tell outcome
Figure 4. Methods of Blinding Outcome Assessors Depending on the Primary Outcome Considered
doi:10.1371/journal.pmed.0040061.g004
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Methods of Blindingassessors the treatment they received. In fact, a study
comparing splinting and surgery in the treatment of carpal
tunnel syndrome involved an attempt to blind the outcome
assessor by encouraging the participants not to reveal their
treatment and by masking the surgical scar. Despite these
efforts, at the end of the trial assessors guessed correctly the
treatment performed [53]. However, asking assessors to guess
treatment assignment during a RCT may not be adequate for
assessing the success of blinding [15,16,54,55]. Authors have
suggested that the success of blinding should be systemati-
cally assessed in RCTs [14]. However, this recommendation
was vigorously debated [15,54,56]. In fact, when asking
participants to guess treatment assignment, those feeling
better will tend to guess they are receiving the experimental
treatment rather then the control treatment. Consequently,
if the treatment is effective, the success of blinding may be
discussed although the method of blinding was adequate.
Blinding is more likely to be considered successful when a
treatment is ineffective. Finally, for participant-reported
outcomes, for which the participant is the outcome assessor,
if no methods can overcome the difﬁculties in establishing
and maintaining blinding of participants, no methods should
be used so as to avoid ascertainment bias by a blinded
outcome assessment.
The description of all these methods also highlights some
issues such as the possible economic burden of blinding
within these trials that might well be substantial and requires
additional investigation. Further, some methods such as
blinding patients to the study hypothesis could lead to partial
blinding, and the success of these methods could be
questionable [18].
Limitations
Our study might not have captured some speciﬁc methods
of blinding. In fact, we assessed only RCTs published in high-
impact-factor journals during 2004. However, our aim was
not to be exhaustive but to provide a description of several
possible methods of blinding. Furthermore, we added reports
found by searching reference lists of relevant selected articles
or reports known by members of our team or experts in this
ﬁeld. In addition, this study assessed only the reporting of
trials, not the trials themselves, and some methods might not
have been reported [10,57]. However, we allowed for high-
lighting creative methods of blinding. Finally, the results are
evolving, and readers are invited to inform us of other
methods of blinding not captured in this survey.
In conclusion, we provide a classiﬁcation of methods of
blinding participants, health care providers, and outcome
assessors in trials of NPT and a detailed description of
methods that could overcome barriers to blinding in such
trials. This classiﬁcation should be helpful for trialists to
determine the method of blinding according to the aim of the
trial and for readers to assess the feasibility of blinding in and
quality of RCTs assessing NPTs.
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Methods of BlindingEditors’ Summary
Background. Well-conducted ‘‘randomized controlled trials’’ are gen-
erally considered to be the most reliable source of information about the
effects of medical treatments. In a randomized trial, the play of chance is
used to decide whether each patient receives the treatment under
investigation, or whether he/she is assigned to a ‘‘control’’ group
receiving the standard treatment for their condition. This helps makes
sure that the two groups of patients receiving the different treatments
are equivalent at the start of the trial. Proper randomization also
prevents doctors from deciding which treatment individual patients are
given, which could distort the results. An additional technique used is
‘‘blinding,’’ which involves taking steps to prevent patients, doctors, or
other people involved in the trial (e.g., those recording measurements)
from finding out which patients have received which treatment. Properly
done, blinding should make sure the results of a trial are more accurate.
This is because in an unblinded study, participants may respond better if
they know they have received a promising new treatment (or worse if
they only got a placebo or an old drug). In addition, doctors and others
in the research team may ‘‘want’’ a particular treatment to perform
better in the trial, and unthinking bias could creep into their measure-
ments or actions. However, blinding is not a simple, single step; the
people carrying out the trial often have to set up a variety of different
procedures.
Why Was This Study Done? The authors of this study had already
conducted research into the way in which blinding is done in trials
involving drug (‘‘pharmacological’’) treatment. Their work was published
in October 2006 in PLoS Medicine. However, concealing from patients the
type of pill that they are being given is much easier than, for example,
concealing whether or not they are having surgery or whether or not
they are having psychotherapy. The authors therefore set out to look at
the methods that are in use for blinding in nonpharmacological trials.
They hoped that a better understanding of the different blinding
methods would help people doing trials to design better trials in the
future, and also help readers to interpret the quality of completed trials.
What Did the Researchers Do and Find? The authors systematically
searched the published medical literature to find all randomized, blinded
drug trials published in just one year (2004) in a number of different
‘‘high-impact’’ journals (well-regarded journals whose articles are often
mentioned in other articles). Then, they classified information from the
published trial reports. They ended up with 145 trial reports, of which
123 described how blinding was done. The trials covered a wide range of
medical conditions and types of treatment. The blinding methods used
mainly involved the use of ‘‘sham’’ procedures. Thus, in 80% of the
studies in which the treatment involved a medical device, a pretend
device had been used to make patients in the control group think they
were receiving treatment. In many of the treatments involving surgery,
researchers had devised elaborate ways of making patients think they
had had an operation. When the treatment involved manipulation (e.g.
physiotherapy or chiropractic), fake ‘‘hands-on’’ techniques were given
to the control patients. The authors of this systematic review classify all
the other techniques that were used to blind both the patients and
members of the research teams. They found that some highly innovative
ideas have been successfully put into practice.
What Do These Findings Mean? The authors have provided a detailed
description of methods that could overcome some barriers of blinding in
clinical trials assessing nonpharmacological treatment. The classification
of the techniques used will be useful for other researchers considering
what sort of blinding they will use in their own research.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040061.
  The James Lind Library has been created to help patients and
researchers understand fair tests of treatments in health care by
illustrating how fair tests have developed over the centuries
  ClinicalTrials.gov, a trial registry created by the US National Institutes
of Health, has an introduction to understanding clinical trials
  The UK National Health Service National Electronic Library for Health
has an introduction to controlled clinical trials
  The CONSORT statement is intended to strengthen evidence-based
reporting of clinical trials
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